Regional
His remarks received strong backlash from the Satrapeeth Majuli
World Health Organization (WHO) sought "additional clarifications" for Covaxin. The organization stated that they need clarifications from the manufactures to conduct a final Emergency Use Listing (EUL) risk-benefit evaluation for the global use of Bharat Biotech's Covaxin.
The technical advisory group will now assemble on November 3 for a final evaluation.So, the Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an autonomous consulting group. This group advises WHO on whether a Covid 19 vaccine can be listed under the EUL mode for emergency use.
"The @WHO independent Technical Advisory Group (TAG) met today & asked for additional clarifications from the manufacturer @BharatBiotech to conduct a final EUL risk-benefit assessment for global use of #Covaxin. In a tweet, it will reconvene for the final assessment on Wednesday, November 3, if data is received soon," WHO chief scientist Dr Soumya Swaminathan declared.
Also Read: Guwahati: Police apprehend three suspects in the elderly couple’s murder case
Bharat Biotech submitted data to WHO on a rolling basis. They also submitted a supplementary report at the UN health body's call on September 27.
Covaxin is the nation's first indigenous COVID-19 vaccine. It was developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research.
The Covaxin has explained 77.8% effectiveness against symptomatic COVID-19. Moreover, 65.2% protection against the new Delta variant.
In June, the company stated it ended the final examination of Covaxin efficiency from Phase 3 trials. Bharat Biotech's Covaxin and AstraZeneca, and Oxford University's Covishield are extensively used vaccines in India.
The WHO has recommended Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India. They have also recommended the use of Johnson & Johnson-Janssen, Moderna, and Sinopharm for emergency treatment.
Leave A Comment